CLAIMS

1. A 5,6-dihydro-α-pyrone of formula (I)



(I)

wherein R is CO_2H or CH_3 and each of R^1 and R^2 is H; or R is CO_2H, one of R^1 and R^2 is H and the other is OH; or, when R is CO_2H, a pharmaceutically or veterinarily acceptable salt thereof.

2. A process for the preparation of a 5,6-dihydro-α-pyrone of formula (I) as defined in claim 1 or a pharmaceutically or veterinarily acceptable salt thereof, which process comprises:

(i) fermenting, in a source of carbon, nitrogen and inorganic salts, fungal strain *Phomopsis* sp. 22502 (CBS 313.96) or a mutant thereof which produces a said 5,6-dihydro-α-pyrone;

(ii) isolating a said 5,6-dihydro-α-pyrone from the fermentation broth; and

(iii) if desired when the isolated said 5,6-dihydro-α-pyrone is the compound of formula (I) wherein R is CO_2H, converting the said 5,6-dihydro-α-pyrone into a pharmaceutically or veterinarily acceptable salt thereof.

3. A process for the preparation of a 5,6-dihydro-α-pyrone of formula (I), as defined in claim 1, wherein R is CH_3, which process comprises esterifying the phomalactone of formula (II):



(II)

with a fatty acid of formula (IIIa):



(IIIa)

4. A pharmaceutical or veterinary composition comprising a pharmaceutically or veterinarily acceptable carrier or diluent and, as active ingredient, a compound as claimed in claim 1.

5. A compound according to claim 1 for use in a method of treatment of the human or animal body by therapy.

6. A compound according to claim 5 for use as a cytokine production inhibitor.

7. A compound according to claim 6 for use as an IL-1 production inhibitor.

8. A compound according to claim 6 for use in the